Replies to post #131275 on Biotech Values

[kamehameha]

500 treatment-naïve GT 2/3 patients

just wonder why only for GT 2/3? another possible restriction on the label - no GT 1 patients.

may be VRUS just wants to avoid a control group with Vertex or Merck products. may work in clinical trials, but physicians most likely will ask for such a comparison.